Qilu Pharmaceutical Co., Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On

A newly approved, homegrown once-weekly GLP-1 receptor agonist is seeking to disrupt a diabetes space in China currently dominated by Novo Nordisk’s same-class global blockbuster Ozempic (semaglutide)

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

As China’s national anti-corruption campaign enters a new stage and goes deep into the local level, physicians in the country are becoming increasingly cautious about issuing prescriptions for high-va